Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma

被引：2
|
作者：
Ebia, Matthew I. [1 ]
Hitchins, Megan P. [2 ]
Hendifar, Andrew E. [1 ,3 ,4 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA USA
[3] Cedars Sinai Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA
[4] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, 8700 Beverly Blvd,Suite 1042AC, Los Angeles, CA 90048 USA
来源：
JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2023年 / 14卷 / 02期
关键词：
Pancreatic ductal adenocarcinoma (PDAC); DNA deficient mismatch repair (DNA dMMR); microsatellite instability (MSI); Lynch syndrome; immunotherapy; CANCER;
D O I：
10.21037/jgo-23-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1175 / 1177
页数：3
相关论文
共 50 条
  • [21] Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC).
    Leal, Alexis Diane
    Paludo, Jonas
    Finnes, Heidi D.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Pancreatic ductal adenocarcinoma with mismatch repair deficiency resected after long-term observation
    Nobuhiko Ogasawara
    Tsunao Imamura
    Rikako Koyama
    Naoko Inoshita
    Atsuhito Nakayama
    Daisuke Hattori
    Yasuo Ito
    Yoshiki Sato
    Tetsuo Tamura
    Masaji Hashimoto
    Clinical Journal of Gastroenterology, 2020, 13 : 959 - 968
  • [23] Immunotherapy with checkpoint inhibitors in mismatch repair deficient (dMMR) cancers: Looking for a needle in a haystack- But, joy on finding one.
    Rauthan, Amit
    Patil, Poonam
    Sood, Tanvi
    Kulkarni, Shriniwas Subhash
    Yashas, Nitin
    Nigade, Gaurav
    Somashekhar, S. P.
    Zaveri, Shabber
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course
    Boeck, S.
    Mehraein, Y.
    Ormanns, S.
    Kruger, S.
    Westphalen, C. Benedikt
    Haas, M.
    Jung, A.
    Kirchner, T.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 438 - 439
  • [25] The Duration of Immunotherapy for Mismatch Repair-Deficient Cancers
    Rousseau, Benoit
    White, James R.
    Cercek, Andrea
    Diaz Jr, Luis A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (08): : 824 - 826
  • [26] Neoadjuvant Immunotherapy for DNA Mismatch Repair-Deficient Pancreatic Cancer: A Single Institution Experience
    Bello, Ricardo J.
    George, Ben
    Kamgar, Mandana
    Ruggeri, Antony
    Christians, Kathleen K.
    Clarke, Callisia N.
    Hall, William
    Erickson, Beth
    Doucette, Saryn
    Hunt, Bryan
    Giorgadze, Tamara
    Evans, Douglas
    Tsai, Susan
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S226 - S227
  • [27] Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials
    Alessandro Paniccia
    Justin Merkow
    Barish H.Edil
    Yuwen Zhu
    Chinese Journal of Cancer Research, 2015, 27 (04) : 376 - 391
  • [28] Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
    Schmiechen, Zoe C.
    Stromnes, Ingunn M.
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [29] Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
    LiKe-Yu
    YuanJia-Long
    TraftonDiego
    WangJian-Xin
    NiuNan
    YuanChun-Hui
    LiuXu-Bao
    ZhengLei
    慢性疾病与转化医学（英文）, 2020, (01) : 6 - 17
  • [30] Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
    Fan, Jia-qiao
    Wang, Meng-Fei
    Chen, Hai-Long
    Shang, Dong
    Das, Jugal K.
    Song, Jianxun
    MOLECULAR CANCER, 2020, 19 (01)
12345